“The Prolyl Oligopeptidase Inhibitor KYP‑2047 Is Not Readily Bioavailable to Bloodstream Form Trypanosomes and Human Myelocytic Leukemia Cells”. Journal of Pharmaceutical Negative Results 6, no. 1 (January 28, 2015): 7–10. Accessed May 14, 2026. https://mail.pnrjournal.com/index.php/home/article/view/84.